Want to see MRNA full AI Analyst Report?
MRNA Stock Chart & Stats
$158.83
-$2.95(-5.17%)
At close: 4:00 PM EDT
$158.83
-$2.95(-5.17%)
Day’s Range― - ―
52-Week Range$22.28 - $254.48
Previous CloseN/A
Volume4.43M
Average Volume (3M)16.52M
Market Cap
$96.65B
Enterprise Value$24.02B
Total Cash (Recent Filing)$5.14B
Total Debt (Recent Filing)$1.29B
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 06, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.98
Shares Outstanding399,235,900
10 Day Avg. Volume20,012,019
30 Day Avg. Volume16,517,233
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue10.78
Enterprise Value/Gross Profit-85.79
Enterprise Value/Ebitda-8.49
Forecast
1Y Price Target
$118.13Price Target Upside-25.63% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)-8.33
Revenue Forecast (FY)$2.10B
Bulls Say, Bears Say
Bulls Say
Balance Sheet FlexibilityLow-to-moderate leverage and substantial cash reserves give Moderna flexibility to fund research, launches, and operating needs while absorbing volatility. Although cash is declining, the balance sheet provides a meaningful buffer as the company works toward broader commercial diversification.
Respiratory Portfolio ExpansionBroader approvals and procurement access expand Moderna’s addressable respiratory market beyond its established COVID franchise. A portfolio of seasonal vaccines can support recurring commercial opportunities and reduce reliance on a single product as launches and international distribution develop.
Operating Cost DisciplineLower manufacturing and operating expenses show progress aligning the cost base with the post-pandemic revenue environment. Continued efficiency could reduce cash burn and improve the economics of future products, allowing more of Moderna’s resources to support launches and pipeline development.
Bears Say
Persistent Losses And Cash BurnOngoing losses and negative free cash flow mean Moderna is not currently self-funding its operations or pipeline. Continued cash consumption can reduce strategic flexibility over time, particularly if commercial launches take longer than expected to offset research and development spending.
COVID Revenue ExposureModerna remains exposed to a mature and potentially declining COVID vaccination market while newer products contribute limited near-term revenue under current guidance. This creates pressure for respiratory launches and pipeline programs to replace the historical contribution of Spikevax.
Clinical And Program Timing RiskThe norovirus setback delays clarity on an important pipeline opportunity and extends the time before potential commercialization. Additional enrollment and seasonal accrual increase execution uncertainty, while event-driven oncology milestones may also take longer to translate into revenue.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $22.28 and its highest was $254.48 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $96.65B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Nov 06, 2026 which is in 15 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Jul 31, 2026. The company reported -$1.97 earnings per share for the quarter, beating the consensus estimate of -$2.032 by $0.062.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -1.11.
How many shares outstanding does Moderna have?
Moderna has 399,235,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$1.97 in its last earnings report, beating expectations of -$2.032. Following the earnings report the stock price went down -5.352%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$118.13 (-25.63% Downside)
$118.13 (-25.63% Downside)
Blogger Sentiment
Neutral
MRNA Sentiment 54%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 43%
Bearish news 57%
Bearish news 57%
Technicals
SMA
Positive
20 days / 200 days
Momentum
794.17%
12-Months-Change
Fundamentals
Return on Equity
-39.20%
Trailing 12-Months
Asset Growth
-8.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.View all MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$118.13
▼(-25.63% Downside)
Technical Analysis
Ionis Pharmaceuticals
―
Protagonist Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
―
Ownership Overview
7.78% Insiders
28.04% Mutual Funds
1.29% Other Institutional Investors
37.26% Public Companies and Individual Investors